IRIS
LADETTO, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.267
NA - Nord America 1.747
AS - Asia 496
Continente sconosciuto - Info sul continente non disponibili 7
SA - Sud America 3
AF - Africa 1
Totale 4.521
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.733
IE - Irlanda 1.345
SE - Svezia 303
UA - Ucraina 215
SG - Singapore 209
HK - Hong Kong 174
DE - Germania 158
IT - Italia 147
CN - Cina 70
FI - Finlandia 53
IN - India 26
CA - Canada 13
GB - Regno Unito 10
CZ - Repubblica Ceca 9
IR - Iran 8
EU - Europa 6
NL - Olanda 6
TR - Turchia 5
RU - Federazione Russa 4
BE - Belgio 3
FR - Francia 3
RO - Romania 3
AT - Austria 2
BR - Brasile 2
PT - Portogallo 2
VN - Vietnam 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
CL - Cile 1
DZ - Algeria 1
GR - Grecia 1
HR - Croazia 1
HU - Ungheria 1
LU - Lussemburgo 1
MX - Messico 1
SY - Repubblica araba siriana 1
Totale 4.521
Salva come PNG Salva come JPEG
Città #
Dublin 1.341
Jacksonville 296
Wilmington 195
Hong Kong 174
Lawrence 174
Princeton 174
San Mateo 145
Singapore 132
Chandler 130
Dearborn 84
Ashburn 40
Piemonte 28
Boardman 27
Beijing 25
Bremen 25
Ann Arbor 23
Fairfield 19
Houston 17
Helsinki 15
Norwalk 15
Andover 14
Des Moines 13
Woodbridge 13
Milan 10
Brno 9
Mülheim 8
Menlo Park 7
Toronto 7
Turin 7
Novara 6
Grafing 5
Hefei 5
Saint Louis 5
Frankfurt am Main 4
Guangzhou 4
Kunming 4
Mumbai 4
Munich 4
Nanjing 4
Alba 3
Alessandria 3
Brussels 3
Buffalo 3
Dallas 3
Elmas 3
Kocaeli 3
Leawood 3
Leipzig 3
Nanchang 3
Ottawa 3
Rimini 3
Seattle 3
Torino 3
Viareggio 3
Zanjan 3
Amsterdam 2
Ardabil 2
Arona 2
Berkhamsted 2
Carpi 2
Cassano Magnago 2
Clifton 2
Dong Ket 2
Eindhoven 2
Fuzhou 2
Giussano 2
Hillsboro 2
Los Angeles 2
Monmouth Junction 2
Pinerolo 2
Rio de Janeiro 2
Roosevelt 2
Salmour 2
San Mauro Torinese 2
Schivenoglia 2
Shenzhen 2
Strasbourg 2
Thorold 2
Tolentino 2
Trecastagni 2
Trieste 2
Venice 2
Vienna 2
Berlin 1
Bisceglie 1
Bologna 1
Cambridge 1
Cárdenas 1
Düsseldorf 1
Gattico 1
Genoa 1
Genova 1
Hangzhou 1
Hebei 1
Horia 1
Iasi 1
Jinan 1
Laglio 1
Lancaster 1
Laurel 1
Totale 3.333
Salva come PNG Salva come JPEG
Nome #
STAble: A novel approach to de novo assembly of RNA-seq data and its application in a metabolic model network based metatranscriptomic workflow 84
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial 72
Comparison of different DNA extraction methods from peripheral blood cells: advices from the Fondazione Italiana Linfomi - MRD Network. 71
MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia 70
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up 69
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 68
COMPARISON OF TWO REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION STRATEGIES FOR MINIMAL RESIDUAL DISEASE EVALUATION IN LYMPHOPROLIFERATIVE DISORDERS: CORRELATION BETWEEN IMMUNOGLOBULIN GENE MUTATION LOAD AND REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION PERFORMANCE 67
Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia 61
CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia 61
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi 57
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study 55
THE HOST GENETIC BACKGROUND OF DNA REPAIR MECHANISMS IS AN INDEPENDENT PREDICTOR OF PROGRESSION AND OVERALL SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA 52
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 51
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 49
The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib 47
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib 47
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma 47
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes 46
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment 45
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia 44
Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi (FIL) ensures superior data quality and improved assessment of clinical outcomes 43
Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients 41
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome 41
TWO MAIN GENETIC PATHWAYS LEAD TO THE TRANSFORMATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO RICHTER SYNDROME 40
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia 40
Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: Results of a multicenter study 40
Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma 38
DEL(13q14) LENGTH MATTERS: AN INTEGRATED ANALYSIS OF GENOMIC, FISH AND CLINICAL DATA IN 169 CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 13q DELETION ALONE OR NORMAL KARYOTYPE 37
Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation 37
Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial 37
Genetic and phenotypic attributes of splenic marginal zone lymphoma 37
LENALIDOMIDE PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PREDNISONE AND RITUXIMAB IS SAFE AND EFFECTIVE IN UNTREATED, ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A PHASE I STUDY BY THE FONDAZIONE ITALIANA LINFOMI 36
Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy 36
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage 36
Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH 35
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines 35
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial 34
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL) 33
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial 33
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia 32
LOW CD49d AND LONG TELOMERE IDENTIFY A CHRONIC LYMPHOCYTIC LEUKEMIA SUBSET WITH HIGHLY FAVOURABLE OUTCOME 32
Highly sensitive MYD88 l265p mutation detection by droplet digital polymerase chain reaction in waldenström macroglobulinemia 31
Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL) 31
Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial. 30
Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft 30
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 30
Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations 29
The adulthood of MRD detection in MCL 29
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial 28
High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting 28
BRAF gene is not mutated in plasma cell leukemia and multiple myeloma 28
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 28
Induction of robust humoral immunity against SARS-CoV-2 after vaccine administration in previously infected haematological cancer patients 27
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition 27
Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network 27
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma 27
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study 27
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies 26
Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 25
A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors 24
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network 24
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma 24
Spontaneous splenic rupture during induction therapy in acute myeloid leukemia: An unusual case 24
Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term 23
A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients 23
Long-term molecular remission after conventional chemotherapy in a patient with Philadelphia-negative acute lymphoblastic leukemia 23
Quality assessment for PCR-based minimal residual disease in Lymphoma: 10 Years of cross-laboratory standardization process within the fondazione italiana linfomi MRD network 23
Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT 23
Organizational determinants of hospital stay: establishing the basis of a widespread action on more efficient pathways in medical units 22
Controversies in the treatment of follicular lymphoma 22
Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 22
EHA Endorsement of ESMO Clinical Practice Guidelines for Marginal Zone Lymphomas 22
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) 22
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial 22
EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Follicular Lymphoma 22
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 21
Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation 21
Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3 21
Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms 21
ESMO Consensus Conference on malignant lymphoma: General perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma 21
A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease 21
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival 21
Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas 21
Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests 21
Central nervous system relapse in a patient with mantle cell lymphoma in continuous clinical and molecular remission at six years since autografting 21
Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance 20
Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment 20
Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma 20
Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients 20
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma 20
Osteonecrosis of the Jaws (ONJ) after Bisphosphonate Treatment in Patients with Multiple Myeloma: Decreasing ONJ Incidence after Adoption of Preventive Measures 20
Home management of hematological patients requiring hospital admission 20
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR 20
The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 {alpha} (HIF-1{alpha}) activity: involvement in myeloma-induced angioge 20
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 20
Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study 20
Hematopoietic Stem Cells (HSC) and Granulocyte Macrophage Progenitors (GMP) are the Oxidative Stress Targets in Low/Intermediate-1 Risk Myelodysplastic Syndromes 19
Droplet digital PCR for minimal residual disease detection in mature lymphoproliferative disorders 19
The mutation of N-ras oncogene does not involve myeloid and erythroid lineages in a case of multiple myeloma 19
Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: An individual patient-level analysis of multiple randomized trials 19
Totale 3.315
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.993
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.993
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020236 0 0 0 0 0 54 72 17 32 31 30 0
2020/2021628 30 14 28 2 29 5 100 88 159 6 158 9
2021/2022794 4 20 143 55 47 0 16 16 81 13 172 227
2022/20231.966 179 37 76 18 69 123 41 93 1.251 8 50 21
2023/2024708 17 31 30 12 160 5 176 10 6 16 38 207
2024/2025147 45 9 42 14 22 15 0 0 0 0 0 0
Totale 4.772